Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion

Abstract

A phase I and pharmacokinetic study of tiazofurin (NSC 286193), a C-nucleoside that inhibits IMP dehydrogenase, has been completed. The drug was administered by continuous infusion over 5 days. The maximum tolerated dose was 1650 mg/m2 per day, neurological toxicity being the dose-limiting factor. Gastrointestinal and hematological toxicity were mild. A… (More)
DOI: 10.1007/BF00256168

Topics

4 Figures and Tables